Anika Therapeutics Sees FY2026 Sales $114.000M-$122.500M vs $116.351M Est
Benzinga Newsdesk 8 months ago
NewsGuidance
Fiscal 2026 GuidanceAnika is providing the following 2026 guidance:Total Company Revenue between $114 and $122.5 million, up 1% to 9% year over yearCommercial Channel, $53 to $58 million, maintaining up 10% to 20% year
Fiscal 2026 Guidance
Anika is providing the following 2026 guidance:
- Total Company Revenue between $114 and $122.5 million, up 1% to 9% year over year
- Commercial Channel, $53 to $58 million, maintaining up 10% to 20% year over year
- OEM Channel, $61 to $64.5 million, maintaining flat to modestly lower year over year
- Adjusted EBITDA as a percent of revenue to 5% to 10%, reflecting higher revenues and reduced expenses offset by modestly lower U.S. pricing dynamics.